3:53 PM
 | 
Nov 30, 2018
 |  BC Extra  |  Clinical News

Trial registry shows He targeting PCSK9 in human embryos

Chinese scientist Jiankui He is conducting a second germline gene editing trial using CRISPR to target PCSK9 in human embryos, according to a retrospective clinical trial listing on the Chinese clinical trial registry.

Chinese researchers and the scientific community condemned He's revelation Sunday that he used CRISPR to genetically modify two human babies by removing the CC chemokine receptor 5 (CCR5) gene in the embryos "to protect the girls from future HIV infection" (see “Chinese Scientists Rebuke Scientist for CRISPR Babies; a “Huge Blow” to Country’s Reputation”).

At the International Summit on Human Genome Editing held in Hong Kong this week, participants expressed concern that other "surreptitious" germline gene editing experiments could be ongoing. He presented...

Read the full 563 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >